CCCP: A CCD Controller for Counting Photons

CCCP, a CCD Controller for Counting Photons, is presented. This new controller uses a totally new clocking architecture and allows to drive the CCD in a novel way. Its design is optimized for the driving of EMCCDs at up to 20MHz of pixel rate and fast vertical transfer. Using this controller, the dominant source of noise of EMCCDs at low flux level and high frame rate, the Clock Induced Charges, were reduced to 0.001 - 0.0018 electron/pixel/frame (depending of the electron multiplying gain), making efficient photon counting possible. CCCP will be deployed in 2009 on the ESO NTT through the 3D-NTT1 project and on the SOAR through the BTFI project.Comment: 10 pages, 10 figures, to appear in "Ground-based and Airborne Instrumentation for Astronomy II" SPIE conference, Marseille, 23-28 June 200

Vote choice in one round and two round elections

Nous proposons un modèle de vote stratégique dans lequel la décision de supporter ou non un candidat dépend de B, le bénéfice associé à l'élection de ce candidat, et de V, la viabilité perçue du candidat. Nous testons ce modèle sur des données obtenues lors d'une série d'expériences dans les quelles les participants votaient dans huit élections successives, quatre suivant la règle de vote à un seul tour, et quatre suivant le vote à deux tours. Nous montrons que le même modèle s'applique aux deux systèmes, bien que l'impact de la viabilité soit légèrement plus faible dans le cas des élections à deux tours.Elections, système de vote, comportement stratégique

Extreme faint flux imaging with an EMCCD

An EMCCD camera, designed from the ground up for extreme faint flux imaging, is presented. CCCP, the CCD Controller for Counting Photons, has been integrated with a CCD97 EMCCD from e2v technologies into a scientific camera at the Laboratoire d'Astrophysique Experimentale (LAE), Universite de Montreal. This new camera achieves sub-electron read-out noise and very low Clock Induced Charge (CIC) levels, which are mandatory for extreme faint flux imaging. It has been characterized in laboratory and used on the Observatoire du Mont Megantic 1.6-m telescope. The performance of the camera is discussed and experimental data with the first scientific data are presented.Comment: 33 pages, 17 figures, accepted for publication in PAS

Efficacy of an adjunctive brief psychodynamic psychotherapy to usual inpatient treatment of depression: rationale and design of a randomized controlled trial.

BACKGROUND: A few recent studies have found indications of the effectiveness of inpatient psychotherapy for depression, usually of an extended duration. However, there is a lack of controlled studies in this area and to date no study of adequate quality on brief psychodynamic psychotherapy for depression during short inpatient stay exists. The present article describes the protocol of a study that will examine the relative efficacy, the cost-effectiveness and the cost-utility of adding an Inpatient Brief Psychodynamic Psychotherapy to pharmacotherapy and treatment-as-usual for inpatients with unipolar depression. METHODS/DESIGN: The study is a one-month randomized controlled trial with a two parallel group design and a 12-month naturalistic follow-up. A sample of 130 consecutive adult inpatients with unipolar depression and Montgomery-Asberg Depression Rating Scale score over 18 will be recruited. The study is carried out in the university hospital section for mood disorders in Lausanne, Switzerland. Patients are assessed upon admission, and at 1-, 3- and 12- month follow-ups. Inpatient therapy is a manualized brief intervention, combining the virtues of inpatient setting and of time-limited dynamic therapies (focal orientation, fixed duration, resource-oriented interventions). Treatment-as-usual represents the best level of practice for a minimal treatment condition usually proposed to inpatients. Final analyses will follow an intention-to-treat strategy. Depressive symptomatology is the primary outcome and secondary outcome includes measures of psychiatric symptomatology, psychosocial role functioning, and psychodynamic-emotional functioning. The mediating role of the therapeutic alliance is also examined. Allocation to treatment groups uses a stratified block randomization method with permuted block. To guarantee allocation concealment, randomization is done by an independent researcher. DISCUSSION: Despite the large number of studies on treatment of depression, there is a clear lack of controlled research in inpatient psychotherapy during the acute phase of a major depressive episode. Research on brief therapy is important to take into account current short lengths of stay in psychiatry. The current study has the potential to scientifically inform appropriate inpatient treatment. This study is the first to address the issue of the economic evaluation of inpatient psychotherapy. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry (ACTRN12612000909820)

HPLC-AAS interfaces for the determination of ionic alkyllead, arsonium and selenonium compounds

Three direct interfaces for coupling high performance liquid chromatography (HPLC) with atomic absorption spectrometry (AAS) were developed and optimized for the determination of ionic organolead, organoselenium and organoarsenic compounds. The first all-quartz interface consisted of a thermospray nebulizer and a flame microatomizer in which ionic alkyllead analytes (R$sb{ rm n}$Pb$sp{ rm (4-n)+};$ R = CH$sb3,$ C$sb2$H$sb5)$ were atomized by a methanol (from HPLC eluent)-oxygen kinetic flame, and channeled in a quartz tube (atom keeper) mounted into the AAS optical beam. Alternately, the classical electrothermal atomization technique for organolead species (quartz furnace under hydrogen atmosphere) was coupled with a post-column derivatization-volatilization apparatus based on the ethylation of ionic alkylleads by sodium tetraethylborate. The limits of detection provided by these two approaches were 1.0-3.4 ng and 0.10-0.15 ng, respectively. Arsonium ((CH$sb3) sb3$RAs$sp+;$ R = CH$sb3,$ CH$sb2$CH$sb2$OH, CH$sb2$COOH) and selenonium ((CH$sb3) sb2$RSe$sp+;$ R = CH$sb3,$ CH$sb2$CH$sb2$OH) species were quantified using a novel HPLC-AAS approach based on a direct coupling of three processes: thermospray nebulization, thermochemical hydride generation using hydrogen gas, and diffuse flame atomization. Direct evidences for the thermochemical hydride generation process was obtained by injecting (CH$sb3) sb3$SeI and SeO$sb2$ into the interface and capturing the gaseous end products in liquid chemical traps specific for SeH$sb2$ and Se(IV). Both analytes were derivatized to SeH$sb2$ only in the presence of hydrogen in the interface. Reverse- and normal-phase high pressure liquid chromatographic methods were also developed and adapted for the HPLC-AAS analyses of alkyllead, arsonium and selenonium compounds in real samples. The limit of detection of the arsonium and selenonium cations were 7.6-13.3 ng and 31.0-43.9 ng, respectively